Recent developments in C5/C5a inhibitors

Proctor, Lavinia M., Woodruff, Trent M. and Taylor, Stephen M. (2006) Recent developments in C5/C5a inhibitors. Expert Opinion On Therapeutic Patents, 16 4: 445-458. doi:10.1517/13543776.16.4.445

Author Proctor, Lavinia M.
Woodruff, Trent M.
Taylor, Stephen M.
Title Recent developments in C5/C5a inhibitors
Journal name Expert Opinion On Therapeutic Patents   Check publisher's open access policy
ISSN 1354-3776
Publication date 2006-04-01
Year available 2006
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1517/13543776.16.4.445
Open Access Status Not yet assessed
Volume 16
Issue 4
Start page 445
End page 458
Total pages 14
Place of publication London
Publisher Ashley Publications Ltd
Language eng
Subject C1
320599 Pharmacology not elsewhere classified
730102 Immune system and allergy
111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
1107 Immunology
Abstract Complement factor 5a (C5a) is formed upon complement system activation in response to infection, injury or disease. Whilst C5a is a potent mediator of immune and inflammatory processes, excessive production or inadequate regulation of C5a has been implicated in the pathogenesis of numerous immuno-inflammatory diseases, predominantly through experimental studies utilising animal models of disease. Both acute and chronic conditions may benefit from C5a inhibition, including rheumatoid arthritis, inflammatory bowel disease, asthma, psoriasis, haemorrhagic shock and neurodegenerative conditions. The potentially broad clinical application for treatments that inhibit the activity of C5a at C5a receptors and the large global market for anti-inflammatory therapeutics have made C5a and the C5a receptor attractive targets for academic and commercial drug development programmes. in the past 5 years, interest in C5a as a drug target has grown substantially, and this activity has resulted in a collection of patents and scientific papers reporting novel C5a and C5a receptor inhibitors and antagonists, and generated a secondary stream of patent applications broadly claiming the use of C5/C5a inhibitors as a method of treating various immune and inflammatory conditions. This paper will review the physiology and pathophysiology of C5a and discuss the development of C5a and C5a receptor inhibitors in light of the recent scientific and patent literature.
Keyword Anti-c5 Antibody
C5a Antagonist
C5a Receptor (c5ar)
Medicine, Legal
Pharmacology & Pharmacy
C5a Receptor Antagonist
Ischemia-reperfusion Injury
Adhesion Molecule Expression
Complement Fragments C5a
Human Anaphylatoxin C5a
Affinity Binding-sites
Dendritic Cells
Q-Index Code C1
Institutional Status UQ
Additional Notes This document is a journal review.

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Excellence in Research Australia (ERA) - Collection
2007 Higher Education Research Data Collection
School of Biomedical Sciences Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 9 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 10 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 19:09:26 EST